OPLS-DA modelling with an optimised threshold diagnosed IgG4-RD – as opposed to PSC – with an accuracy of 86%, sensitivity of 96%, and specificity of 70% (figure 1), adjusted for age, gender, comorbidities, serum IgG4 level and medicalisations. Both IgG4-RD and PSC were independently distinguishable from HC with an accuracy of 96% and 91%, respectively. When only IgG4-SC patients (n=23) were included with large-duct PSC patients (n=81), the accuracy was 88%. When IBD was excluded as a comorbid condition (IgG4-SC n=20, PSC n=22), the diagnostic AUC was 0.998 (0.991–1.000).

The metabolomic signature determined by serum NMR in patients with IgG4-RD and more specifically IgG4-SC, is distinct from PSC and HC in our cohort. Metabolomic profiling has the potential to be incorporated as an additional criterion to improve the diagnosis of IgG4-RD and help distinguish IgG4-SC from PSC.

**OPPORTUNITIES TO INTERVENE AFTER EARLY DETECTION OF ALCOHOL RELATED LIVER DISEASE**

Twonge Jason Nyirenda*, Lucy Turner, Rebecca Bishop, Ian Rowe, Richard Parker. Leeds Teaching Hospitals NHS Trust, Leeds, UK

10.1136/gutjnl-2021-BASL5

Alcohol related liver disease (ALD) is common worldwide and a frequent cause of ill health and death, particularly amongst younger people. We have previously shown that histological progression is slow. We examined the clinical progression of ALD and how interventions following detection of liver disease could alter the natural history.

The electronic health records of patients with ALD were examined retrospectively to identify: time of first liver blood tests (LBt), first abnormal LBt, time of diagnosis of liver disease and first episode of decompensation of liver disease. Decompensated liver disease was defined as: ascites, varical bleeding, hepatic encephalopathy, alcoholic hepatitis or hepatorenal syndrome. Attendance at alcohol services and/or hepatology services was noted. Baseline characteristics including laboratory and anthropometric data were recorded. Patient’s postcode was used as a measure of deprivation. Data were analysed by Kaplan Meier survival analysis and Cox proportional hazard analysis, using R. All patients gave informed consent for their records to be accessed as part of the ALL-HEAL study.

Seventy-three patients with decompensated liver disease were analysed. The median delay from the detection of disease (i.e. first abnormal LBt) to decompensated ALD was 6.6 years (95% CI 4.7 – 10.1 years). In Cox proportional hazard analysis, independent factors that influenced time from detection to decompensation were: age, bilirubin, albumin, INR, platelets and mean cell volume. Engagement with alcohol services was the strongest predictor of time to decompensation: hazard ratio 0.50 (0.31 – 0.80, p=0.004). The median time to decompensation in patients who engaged with alcohol services was 10.3 years (8.6 – 12) versus 3.9 years (1.3 – 6.6) in those who did not (log rank p<0.001). Excluding patients with decompensation within 3 months of first abnormal LBt did not change the pattern of results but statistical significance was lost.

The natural history of ALD allows for a significant period of time between detection and liver-related morbidity, Attendance at alcohol services is associated with a significant delay between detection to decompensation in this cohort of patients. These data can support efforts to detect liver disease amongst persons with alcohol use disorder.

**006 AMINOBISPHONATES ENHANCE LIVER-RESIDENT GAMMA DELTA T CELLS FOR EFFICIENT TARGETING OF HEPATOCELLULAR CARCINOMA**

Nekisa Zaken1, Andrew Hall2, Leo Swadling1, Laura J Pallett1, Nathalie M Schmidt1, Mariana O Diniz1, Stephanie Kuczkowicz1, Oliver E Amin1, Amir Gander4, Massimo Pinzani1, Brian R Davidson1, Alberto Quaglia2, Maia K Maini1. 1Division of Infection and Immunity, University College London, UK; 2Department of Cellular Pathology, Royal Free London NHS Foundation Trust, UK; 3Division of Surgery, University College London, UK; 4Institute for Liver and Digestive Health, Royal Free London NHS Foundation Trust, UK

10.1136/gutjnl-2021-BASL6

Background More effective immunotherapeutic strategies are urgently needed for hepatocellular carcinoma (HCC). Gamma delta (γδ) T-cells are attractive candidates for cancer immunotherapy due to their potent cytotoxicity, tissue localisation and HLA-unrestricted tumour reactivity. We characterised liver and tumour infiltrating γδ T-cells in HCC, and explored whether modulating features of tissue-residency could provide a novel immunotherapeutic approach.

Methods Lymphocytes isolated from paired blood, liver, and tumoural tissue from patients with HCC (n=31) in comparison to colorectal cancer liver metastases (n=30) were analysed by multiparameter flow cytometry. γδ T-cell counts were determined by immunostaining. Long-lived persistence of intrahepatic γδ T-cells was examined using donor and recipient HLA-mismatched liver allografts (7–11 years post liver transplantation). Aminobisphosphonate (Zoledronic acid, ZOL) and IL-2 expanded blood Vδ2 T-cells, intrahepatic lymphocytes, and tumour-infiltrating lymphocytes, were co-cultured with human hepatoma cell-lines (HepG2, HuH7) pre-treated with ZOL to promote tumour-cell phosphoantigen accumulation for Vδ2 T-cell receptor activation.

Results Higher intratumoural γδ T-cell counts were associated with smaller HCC tumour size and greater 3-year patient survival (p<0.01). γδ T-cells exhibited a tissue-resident memory (TRM) phenotype (CD69+CD49a+) in human liver and HCC, with superior anti-tumour cytokine production and long-lived persistence in the liver (>10 years), an attractive profile to recapitulate with immunotherapy. A subset of γδ T-cells, Vδ2 T-cells, were selectively depleted within HCC but displayed the highest γδ TRM phenotype. In vitro expansion of blood Vδ2 T-cells using clinically approved ZOL and IL-2 induced a de novo TRM phenotype with improved cytotoxicity. Furthermore, direct sensitisation of hepatoma cell-lines with ZOL enhanced the anti-tumour function (IFNγ,TNFα) of co-cultured expanded Vδ2 T-cells and Vδ2 TRM cells isolated from HCC livers and tumours, with a significant increase in tumour-cell lysis.

Conclusion Liver-resident γδ T-cells possess beneficial and long-lived immunotherapeutic properties. Our findings indicate a novel immunotherapeutic strategy for HCC, combining the use of aminobisphosphonates to induce γδ TRM for potential adoptive cell transfer, with intra-tumoural delivery to sensitise HCC for more efficient γδ T-cell based targeting.